Ausgabe 6/2019
Inhalt (22 Artikel)
Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling
Jin Gao, Huimin Hu, Xuesong Wang
d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro
Henry Oppermann, Martina Matusova, Annegret Glasow, Johannes Dietterle, Rainer Baran-Schmidt, Karsten Neumann, Jürgen Meixensberger, Frank Gaunitz
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
Niharika B. Mettu, Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, Hope Uronis
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
Makoto Natsume, Takaya Shimura, Hiroyasu Iwasaki, Yusuke Okuda, Mika Kitagawa, Yasuyuki Okamoto, Kazuki Hayashi, Hiromi Kataoka
Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
Takashi Kosaka, Hirotoshi Akiyama, Hiroshi Miyamoto, Sho Sato, Yusaku Tanaka, Kei Sato, Chikara Kunisaki, Itaru Endo
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
Christophe Massard, Jean-Charles Soria, Jürgen Krauss, Michael Gordon, Albert Craig Lockhart, Erik Rasmussen, Vijay V. Upreti, Sonal Patel, Gataree Ngarmchamnanrith, Haby Henary
LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma
Shian Liao, Shuxing Xing, Yanhui Ma
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
Takashi Higuchi, Kentaro Miyake, Norihiko Sugisawa, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study
Hui Li, Jian Zeng, Xiangyu Jin, Xinmin Yu, Guoming Zhou, Wei Hong
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
Murat Araz, Mustafa Karaagac, Levent Korkmaz, Lokman Koral, Fatih Inci, Ismail Beypinar, Mukremin Uysal, Mehmet Artac
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer
Satoru Tanaka, Nobuki Matsunami, Hirotaka Morishima, Naofumi Oda, Tsutomu Takashima, Satoru Noda, Shinichiro Kashiwagi, Yukie Tauchi, Yuka Asano, Kosei Kimura, Hiroya Fujioka, Risa Terasawa, Kanako Kawaguchi, Ayana Ikari, Takashi Morimoto, Shintaro Michishita, Toshihiro Kobayashi, Junna Sakane, Toshikatsu Nitta, Nayuko Sato, Norihiro Hokimoto, Yukihiro Nishida, Mitsuhiko Iwamoto
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation
Sunil Adige, Rena G. Lapidus, Brandon A. Carter-Cooper, Alison Duffy, Ciera Patzke, Jennie Y. Law, Maria R. Baer, Nicholas P. Ambulos, Ying Zou, Søren M. Bentzen, Ashkan Emadi
Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique
Kotaro Kimura, Keishi Yamasaki, Koji Nishi, Kazuaki Taguchi, Masaki Otagiri
Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study
Makoto Sakai, Makoto Sohda, Hideyuki Saito, Kengo Kuriyama, Tomonori Yoshida, Yuji Kumakura, Keigo Hara, Takehiko Yokobori, Tatsuya Miyazaki, Kazutoshi Murata, Shin-ei Noda, Takashi Nakano, Hiroyuki Kuwano, Ken Shirabe
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil
Masae Sekido, Ken-ichi Fujita, Yutaro Kubota, Hiroo Ishida, Takehiro Takahashi, Ryotaro Ohkuma, Takuya Tsunoda, Fumihiro Ishikawa, Motoko Shibanuma, Yasutsuna Sasaki
Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients
Derya Kıvrak Salim, Tuğba Akın Telli, Ali Murat Tatlı, Sadettin Kılıçkap, Perran Fulden Yumuk
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Whitney P. Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, Rachelle Mack, Sharareh Monemi, Ihsan Nijem, Sandhya Girish, Christie Freeman, Debora Fumagalli, Robin McConnell, Guy Jerusalem, Chris Twelves, José Baselga, Gunter von Minckwitz, José Bines, Amit Garg
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents
Tim Cardilin, Joachim Almquist, Mats Jirstrand, Astrid Zimmermann, Floriane Lignet, Samer El Bawab, Johan Gabrielsson
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Fernando Rivera, C. Romero, P. Jimenez-Fonseca, M. Izquierdo-Manuel, A. Salud, E. Martínez, M. Jorge, V. Arrazubi, J. C. Méndez, P. García-Alfonso, M. Reboredo, J. Barriuso, N. Muñoz-Unceta, R. Jimeno, C. López
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
Roger M. Phillips, Paul M. Loadman, Guru Reddy
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias
Muhammad Umer Farooq, Fahad Mushtaq, Anum Farooq, Danish Hassan Khan, Muhammad Ayaz Mir
Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
Saadettin Kilickap, Sevgen Onder, Omer Dizdar, Mustafa Erman, Aysegul Uner